Immunotherapy Drugs Market Outlook by Type (Checkpoint Inhibitors, Vaccines), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases), End User (Hospitals and Clinics, Individuals) - Global Industry Revenue Estimation and Demand Forecast to 2030

Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segment

1.4.1. Market size breakdown, by type

1.4.2. Market size breakdown, by therapy area

1.4.3. Market size breakdown, by end user

1.4.4. Market size breakdown, by region

1.5. Market Data Reporting Unit

1.5.1. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

6.1. Market Dynamics

6.1.1. Trends

6.1.2. Drivers

6.1.3. Restraints/challenges

6.1.4. Impact analysis of drivers/restraints

6.2. Impact of COVID-19

6.3. Porter’s Five Forces Analysis

6.3.1. Bargaining power of buyers

6.3.2. Bargaining power of suppliers

6.3.3. Threat of new entrants

6.3.4. Intensity of rivalry

6.3.5. Threat of substitutes

Chapter 7. Global Market

7.1. Overview

7.2. Market Revenue, by Type (2017–2030)

7.2.1. Checkpoint inhibitors market revenue, by brand (2017–2030)

7.2.2. Vaccines market revenue, by type (2017–2030)

7.2.3. Vaccines market revenue, by brand (2017–2030)

7.3. Market Revenue, by Therapy Area (2017–2030)

7.4. Market Revenue, by End User (2017–2030)

7.5. Market Revenue, by Region (2017–2030)

Chapter 8. North America Market

8.1. Overview

8.2. Market Revenue, by Type (2017–2030)

8.2.1. Checkpoint inhibitors market revenue, by brand (2017–2030)

8.2.2. Vaccines market revenue, by type (2017–2030)

8.2.3. Vaccines market revenue, by brand (2017–2030)

8.3. Market Revenue, by Therapy Area (2017–2030)

8.4. Market Revenue, by End User (2017–2030)

8.5. Market Revenue, by Country (2017–2030)

Chapter 9. Europe Market

9.1. Overview

9.2. Market Revenue, by Type (2017–2030)

9.2.1. Checkpoint inhibitors market revenue, by brand (2017–2030)

9.2.2. Vaccines market revenue, by type (2017–2030)

9.2.3. Vaccines market revenue, by brand (2017–2030)

9.3. Market Revenue, by Therapy Area (2017–2030)

9.4. Market Revenue, by End User (2017–2030)

9.5. Market Revenue, by Country (2017–2030)

Chapter 10. APAC Market

10.1. Overview

10.2. Market Revenue, by Type (2017–2030)

10.2.1. Checkpoint inhibitors market revenue, by brand (2017–2030)

10.2.2. Vaccines market revenue, by type (2017–2030)

10.2.3. Vaccines market revenue, by brand (2017–2030)

10.3. Market Revenue, by Therapy Area (2017–2030)

10.4. Market Revenue, by End User (2017–2030)

10.5. Market Revenue, by Country (2017–2030)

Chapter 11. LATAM Market

11.1. Overview

11.2. Market Revenue, by Type (2017–2030)

11.2.1. Checkpoint inhibitors market revenue, by brand (2017–2030)

11.2.2. Vaccines market revenue, by type (2017–2030)

11.2.3. Vaccines market revenue, by brand (2017–2030)

11.3. Market Revenue, by Therapy Area (2017–2030)

11.4. Market Revenue, by End User (2017–2030)

11.5. Market Revenue, by Country (2017–2030)

Chapter 12. MEA Market

12.1. Market Revenue, by Type (2017–2030)

12.1.1. Checkpoint inhibitors market revenue, by brand (2017–2030)

12.1.2. Vaccines market revenue, by type (2017–2030)

12.1.3. Vaccines market revenue, by brand (2017–2030)

12.2. Market Revenue, by Therapy Area (2017–2030)

12.3. Market Revenue, by End User (2017–2030)

12.4. Market Revenue, by Country (2017–2030)

Chapter 13. Competitive Landscape

13.1. List of Market Players and Their Offerings

13.2. Competitive Benchmarking of Key Players

13.3. Product Benchmarking of Key Players

13.4. Recent Strategic Developments

Chapter 14. Company Profiles

14.1. Eli Lilly and Company

14.1.1. Business overview

14.1.2. Product and service offerings

14.1.3. Key financial summary

14.2. Sanofi

14.2.1. Business overview

14.2.2. Product and service offerings

14.2.3. Key financial summary

14.3. Novartis AG

14.3.1. Business overview

14.3.2. Product and service offerings

14.3.3. Key financial summary

14.4. AbbVie Inc.

14.4.1. Business overview

14.4.2. Product and service offerings

14.4.3. Key financial summary

14.5. F. Hoffmann-La Roche Ltd.

14.5.1. Business overview

14.5.2. Product and service offerings

14.5.3. Key financial summary

14.6. AstraZeneca PLC

14.6.1. Business overview

14.6.2. Product and service offerings

14.6.3. Key financial summary

14.7. Merck & Co. Inc.

14.7.1. Business overview

14.7.2. Product and service offerings

14.7.3. Key financial summary

14.8. GlaxoSmithKline plc

14.8.1. Business overview

14.8.2. Product and service offerings

14.8.3. Key financial summary

14.9. Takeda Pharmaceutical Company Limited

14.9.1. Business overview

14.9.2. Product and service offerings

14.9.3. Key financial summary

14.10. Bristol-Myers Squibb Company

14.10.1. Business overview

14.10.2. Product and service offerings

14.10.3. Key financial summary

14.11. C.H. Boehringer Sohn AG & Co. KG

14.11.1. Business overview

14.11.2. Product and service offerings

14.11.3. Key financial summary

14.12. Amgen Inc.

14.12.1. Business overview

14.12.2. Product and service offerings

14.12.3. Key financial summary

14.13. Johnson & Johnson Services Inc.

14.13.1. Business overview

14.13.2. Product and service offerings

14.13.3. Key financial summary

14.14. Bayer AG

14.14.1. Business overview

14.14.2. Product and service offerings

14.14.3. Key financial summary

14.15. Teva Pharmaceutical Industries Limited

14.15.1. Business overview

14.15.2. Product and service offerings

14.15.3. Key financial summary

Chapter 15. Appendix

15.1. Abbreviations

15.2. Sources and References

15.3. Related Reports

 

LIST OF TABLES

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2022)

TABLE 5 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2023–2026)

TABLE 6 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2027–2030)

TABLE 7 GLOBAL CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2017–2022)

TABLE 8 GLOBAL CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2023–2026)

TABLE 9 GLOBAL CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2027–2030)

TABLE 10 GLOBAL VACCINES MARKET, BY TYPE, $M (2017–2022)

TABLE 11 GLOBAL VACCINES MARKET, BY TYPE, $M (2023–2026)

TABLE 12 GLOBAL VACCINES MARKET, BY TYPE, $M (2027–2030)

TABLE 13 GLOBAL VACCINES MARKET, BY BRAND, $M (2017–2022)

TABLE 14 GLOBAL VACCINES MARKET, BY BRAND, $M (2023–2026)

TABLE 15 GLOBAL VACCINES MARKET, BY BRAND, $M (2027–2030)

TABLE 16 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2022)

TABLE 17 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2023–2026)

TABLE 18 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2027–2030)

TABLE 19 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2022)

TABLE 20 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2023–2026)

TABLE 21 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2027–2030)

TABLE 22 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, $M (2017–2022)

TABLE 23 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, $M (2023–2026)

TABLE 24 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, $M (2027–2030)

TABLE 25 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2022)

TABLE 26 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2023–2026)

TABLE 27 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2027–2030)

TABLE 28 NORTH AMERICA CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2017–2022)

TABLE 29 NORTH AMERICA CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2023–2026)

TABLE 30 NORTH AMERICA CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2027–2030)

TABLE 31 NORTH AMERICA VACCINES MARKET, BY TYPE, $M (2017–2022)

TABLE 32 NORTH AMERICA VACCINES MARKET, BY TYPE, $M (2023–2026)

TABLE 33 NORTH AMERICA VACCINES MARKET, BY TYPE, $M (2027–2030)

TABLE 34 NORTH AMERICA VACCINES MARKET, BY BRAND, $M (2017–2022)

TABLE 35 NORTH AMERICA VACCINES MARKET, BY BRAND, $M (2023–2026)

TABLE 36 NORTH AMERICA VACCINES MARKET, BY BRAND, $M (2027–2030)

TABLE 37 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2022)

TABLE 38 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2023–2026)

TABLE 39 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2027–2030)

TABLE 40 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2022)

TABLE 41 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2023–2026)

TABLE 42 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2027–2030)

TABLE 43 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 44 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 45 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 46 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2022)

TABLE 47 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2023–2026)

TABLE 48 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2027–2030)

TABLE 49 EUROPE CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2017–2022)

TABLE 50 EUROPE CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2023–2026)

TABLE 51 EUROPE CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2027–2030)

TABLE 52 EUROPE VACCINES MARKET, BY TYPE, $M (2017–2022)

TABLE 53 EUROPE VACCINES MARKET, BY TYPE, $M (2023–2026)

TABLE 54 EUROPE VACCINES MARKET, BY TYPE, $M (2027–2030)

TABLE 55 EUROPE VACCINES MARKET, BY BRAND, $M (2017–2022)

TABLE 56 EUROPE VACCINES MARKET, BY BRAND, $M (2023–2026)

TABLE 57 EUROPE VACCINES MARKET, BY BRAND, $M (2027–2030)

TABLE 58 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2022)

TABLE 59 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2023–2026)

TABLE 60 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2027–2030)

TABLE 61 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2022)

TABLE 62 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2023–2026)

TABLE 63 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2027–2030)

TABLE 64 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 65 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 66 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 67 APAC IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2022)

TABLE 68 APAC IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2023–2026)

TABLE 69 APAC IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2027–2030)

TABLE 70 APAC CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2017–2022)

TABLE 71 APAC CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2023–2026)

TABLE 72 APAC CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2027–2030)

TABLE 73 APAC VACCINES MARKET, BY TYPE, $M (2017–2022)

TABLE 74 APAC VACCINES MARKET, BY TYPE, $M (2023–2026)

TABLE 75 APAC VACCINES MARKET, BY TYPE, $M (2027–2030)

TABLE 76 APAC VACCINES MARKET, BY BRAND, $M (2017–2022)

TABLE 77 APAC VACCINES MARKET, BY BRAND, $M (2023–2026)

TABLE 78 APAC VACCINES MARKET, BY BRAND, $M (2027–2030)

TABLE 79 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2022)

TABLE 80 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2023–2026)

TABLE 81 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2027–2030)

TABLE 82 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2022)

TABLE 83 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2023–2026)

TABLE 84 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2027–2030)

TABLE 85 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 86 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 87 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 88 LATAM IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2022)

TABLE 89 LATAM IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2023–2026)

TABLE 90 LATAM IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2027–2030)

TABLE 91 LATAM CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2017–2022)

TABLE 92 LATAM CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2023–2026)

TABLE 93 LATAM CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2027–2030)

TABLE 94 LATAM VACCINES MARKET, BY TYPE, $M (2017–2022)

TABLE 95 LATAM VACCINES MARKET, BY TYPE, $M (2023–2026)

TABLE 96 LATAM VACCINES MARKET, BY TYPE, $M (2027–2030)

TABLE 97 LATAM VACCINES MARKET, BY BRAND, $M (2017–2022)

TABLE 98 LATAM VACCINES MARKET, BY BRAND, $M (2023–2026)

TABLE 99 LATAM VACCINES MARKET, BY BRAND, $M (2027–2030)

TABLE 100 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2022)

TABLE 101 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2023–2026)

TABLE 102 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2027–2030)

TABLE 103 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2022)

TABLE 104 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2023–2026)

TABLE 105 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2027–2030)

TABLE 106 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 107 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 108 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 109 MEA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2022)

TABLE 110 MEA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2023–2026)

TABLE 111 MEA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2027–2030)

TABLE 112 MEA CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2017–2022)

TABLE 113 MEA CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2023–2026)

TABLE 114 MEA CHECKPOINT INHIBITORS MARKET, BY BRAND, $M (2027–2030)

TABLE 115 MEA VACCINES MARKET, BY TYPE, $M (2017–2022)

TABLE 116 MEA VACCINES MARKET, BY TYPE, $M (2023–2026)

TABLE 117 MEA VACCINES MARKET, BY TYPE, $M (2027–2030)

TABLE 118 MEA VACCINES MARKET, BY BRAND, $M (2017–2022)

TABLE 119 MEA VACCINES MARKET, BY BRAND, $M (2023–2026)

TABLE 120 MEA VACCINES MARKET, BY BRAND, $M (2027–2030)

TABLE 121 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2022)

TABLE 122 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2023–2026)

TABLE 123 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2027–2030)

TABLE 124 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2022)

TABLE 125 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2023–2026)

TABLE 126 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2027–2030)

TABLE 127 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 128 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2023–2026)

TABLE 129 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2027–2030)

TABLE 130 ELI LILLY AND COMPANY – AT A GLANCE

TABLE 131 ELI LILLY AND COMPANY – KEY FINANCIAL SUMMARY

TABLE 132 SANOFI – AT A GLANCE

TABLE 133 SANOFI – KEY FINANCIAL SUMMARY

TABLE 134 NOVARTIS AG – AT A GLANCE

TABLE 135 NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 136 ABBVIE INC. – AT A GLANCE

TABLE 137 ABBVIE INC. – KEY FINANCIAL SUMMARY

TABLE 138 F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE

TABLE 139 F. HOFFMANN-LA ROCHE LTD. – KEY FINANCIAL SUMMARY

TABLE 140 ASTRAZENECA PLC – AT A GLANCE

TABLE 141 ASTRAZENECA PLC – KEY FINANCIAL SUMMARY

TABLE 142 MERCK & CO. INC. – AT A GLANCE

TABLE 143 MERCK & CO. INC. – KEY FINANCIAL SUMMARY

TABLE 144 GLAXOSMITHKLINE PLC – AT A GLANCE

TABLE 145 GLAXOSMITHKLINE PLC – KEY FINANCIAL SUMMARY

TABLE 146 TAKEDA PHARMACEUTICAL COMPANY LIMITED – AT A GLANCE

TABLE 147 TAKEDA PHARMACEUTICAL COMPANY LIMITED – KEY FINANCIAL SUMMARY

TABLE 148 BRISTOL-MYERS SQUIBB COMPANY – AT A GLANCE

TABLE 149 BRISTOL-MYERS SQUIBB COMPANY – KEY FINANCIAL SUMMARY

TABLE 150 C.H. BOEHRINGER SOHN AG & CO. KG – AT A GLANCE

TABLE 151 C.H. BOEHRINGER SOHN AG & CO. KG – KEY FINANCIAL SUMMARY

TABLE 152 AMGEN INC. – AT A GLANCE

TABLE 153 AMGEN INC. – KEY FINANCIAL SUMMARY

TABLE 154 JOHNSON & JOHNSON SERVICES INC. – AT A GLANCE

TABLE 155 JOHNSON & JOHNSON SERVICES INC. – KEY FINANCIAL SUMMARY

TABLE 156 BAYER AG – AT A GLANCE

TABLE 157 BAYER AG – KEY FINANCIAL SUMMARY

TABLE 158 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – AT A GLANCE

TABLE 159 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 CURRENCY CONVERSION RATES FOR USD (2022)

FIG 8 GLOBAL IMMUNOTHERAPY DRUGS MARKET SUMMARY

FIG 9 BARGAINING POWER OF BUYERS

FIG 10 BARGAINING POWER OF SUPPLIERS

FIG 11 THREAT OF NEW ENTRANTS

FIG 12 INTENSITY OF RIVALRY

FIG 13 THREAT OF SUBSTITUTES

FIG 14 GLOBAL IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 15 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2030)

FIG 16 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2030)

FIG 17 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2030)

FIG 18 MAJOR WORLDWIDE MARKETS FOR IMMUNOTHERAPY DRUGS, $M

FIG 19 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 20 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2030)

FIG 21 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2030)

FIG 22 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2030)

FIG 23 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2030)

FIG 24 EUROPE IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 25 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2030)

FIG 26 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2030)

FIG 27 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2030)

FIG 28 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2030)

FIG 29 APAC IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 30 APAC IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2030)

FIG 31 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2030)

FIG 32 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2030)

FIG 33 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2030)

FIG 34 LATAM IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 35 LATAM IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2030)

FIG 36 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2030)

FIG 37 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2030)

FIG 38 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2030)

FIG 39 MEA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 40 MEA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $M (2017–2030)

FIG 41 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $M (2017–2030)

FIG 42 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $M (2017–2030)

FIG 43 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $M (2017–2030)

FIG 44 ELI LILLY AND COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 45 SANOFI – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 46 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 47 ABBVIE INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 48 F. HOFFMANN-LA ROCHE LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 49 ASTRAZENECA PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 50 MERCK & CO. INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 51 GLAXOSMITHKLINE PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 52 TAKEDA PHARMACEUTICAL COMPANY LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 53 BRISTOL-MYERS SQUIBB COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 54 C.H. BOEHRINGER SOHN AG & CO. KG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 55 AMGEN INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 56 JOHNSON & JOHNSON SERVICES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 57 BAYER AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)

FIG 58 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)